Andere Sprachen Race Oncology Limited

Aktien

Markt geschlossen - Australian S.E. Andere Börsenplätze 08:10:37 17.05.2024			% 5 Tage	% 1. Jan.
1,55 ^AUD	-0,96 %		+17,87 %	+84,52 %

26.03.	Race Oncology erhält Analysezertifikat für RC220; Aktien steigen um fast 6%	MT
06.03.	Race Oncology sagt Studie zeigt die Wirksamkeit von Lead Asset in der Blutkrebsbehandlung	MT

Race Oncology's breakthrough in cancer cell treatment	15.05.
Race Oncology Obtains Certificate of Analysis for RC220; Shares Up Almost 6%	26.03.
Race Oncology Limited(ASX:RAC) dropped from S&P/ASX All Ordinaries Index	18.03.
Race Oncology Says Study Shows Lead Asset's Efficacy in Blood Cancer Treatment	06.03.
Race Oncology looks to accelerate clinical development of bisantrene	28.02.
Race Oncology Widens Loss in Fiscal H1	28.02.
Race Oncology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	27.02.
Race Oncology appoints Dr Daniel Tillett as CEO	23.11.
Race Oncology Names CEO; Shares Jump 5%	22.11.
Race Oncology Limited Appoints Daniel Tillett as Chief Executive Officer	21.11.
Race Oncology highlights impressive bisantrene clinical data	07.11.
Race Oncology kicks off safety studies for RC220	09.10.23
Race Oncology Initiates Toxicology, Safety Pharmacology Studies of Chemotherapy Drug	05.10.23
Race Oncology Limited(ASX:RAC) dropped from S&P Global BMI Index	18.09.23
Race Oncology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	30.08.23
Race Oncology Limited Announces Board Changes	22.08.23
Race Oncology at the heart of cancer care	09.08.23
Race Oncology announces deal with manufacturer Ardena to develop companyÃ¢€™s new IV formulation RC220	19.07.23
Race Oncology Secures More R&D Tax Rebate for Fiscal Year 2022; Shares Rise 4%	13.07.23
Race Executes Agreement with Ardena for GMP Manufacturing of RC220	12.07.23

Keine Ergebnisse zu dieser Suche